USA Leonard Paolillo, President of Merz Therapeutics North America, shares what it means to be a growing player in the specialty neurology space. Two years after the company’s acquisition of INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine), and with XEOMIN® (incobotulinumtoxinA) continuing to anchor its portfolio, Paolillo reflects on how Merz…
Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…
Europe Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region Europe Head Dan Staner discusses the company’s long-term ambitions in specialty neurology, while also reflecting on the growing importance of…
See our Cookie Privacy Policy Here
